Plant ID: NPO30686
Plant Latin Name: Citrus hystrix
Taxonomy Genus: Citrus
Taxonomy Family: Rutaceae
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
771927-1
Australia; Bangladesh; Myanmar; Philippines; Indonesia; India; New Caledonia; Cambodia; Trinidad and Tobago; Vietnam; China; Papua New Guinea; Sri Lanka; Thailand; Fiji
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2B6 | Cytochrome P450 2B6 | P20813 | CHEMBL4729 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.810E-13 | 3.942E-09 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 6.931E-13 | 7.547E-09 | CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.039E-12 | 2.206E-08 | CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.968E-12 | 2.947E-08 | CYP2B6, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.120E-12 | 2.947E-08 | ALOX15, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 3.619E-10 | 6.062E-07 | CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 6.510E-10 | 9.451E-07 | CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.024E-08 | 9.695E-06 | CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.782E-08 | 1.552E-05 | CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 3.162E-08 | 2.459E-05 | CYP2B6, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.180E-08 | 4.486E-05 | CYP2B6, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0016712; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 1.207E-07 | 8.478E-05 | CYP2B6, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.502E-07 | 2.971E-04 | CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 9.002E-07 | 5.298E-04 | CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.743E-06 | 3.581E-03 | CYP2C19, CYP2C9 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.210E-05 | 6.129E-03 | CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009056; catabolic process | 1.736E-05 | 8.217E-03 | ALDH1A1, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
CC | GO:0016020; membrane | GO:0031090; organelle membrane | 1.667E-04 | 7.261E-02 | CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, LMNA |
CC | GO:0044464; cell part | GO:0031234; extrinsic component of cytoplasmic side of plasma membrane | 2.944E-02 | 1.000E+00 | ALOX15 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.342E-11 | 3.514E-10 | CYP2C9, CYP2B6, CYP2D6, CYP3A4, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.485E-10 | 1.863E-09 | CYP2C9, ALOX15, CYP3A4, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 5.805E-09 | 2.641E-08 | CYP2C9, CYP2B6, ALOX15, CYP2C19 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 7.042E-09 | 2.641E-08 | CYP2C9, CYP2B6, ALDH1A1, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.131E-08 | 3.392E-08 | CYP2C9, CYP2B6, CYP2D6, CYP3A4 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 6.411E-08 | 1.603E-07 | CYP2C9, CYP2D6, ALOX15, CYP2C19 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.404E-06 | 3.008E-06 | CYP2C9, CYP2B6, ALOX15, ALDH1A1, CYP2C19, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.665E-06 | 6.872E-06 | CYP2C9, CYP3A4, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 1.826E-02 | 3.043E-02 | CYP3A4 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.297E-02 | 3.445E-02 | CYP3A4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |